Valeria Rubinacci

Dr. Valeria Rubinacci

University of Milan, Milan, Lombardy, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
Cclaudia Vanetti
claudia Vanetti
Daria Lucia TrabattoniDaria Lucia Trabattoni
Daria Lucia Trabattoni
MSmarta stracuzzi
marta stracuzzi
AAAntonella Amendola
Antonella Amendola
CFClara Fappani
Clara Fappani
VGVania Giacomet
Vania Giacomet
While the risk of SARS-CoV-2 infection and/or COVID-19 disease progression in the general population has been largely assessed, its impact on HIV-positive individuals remains unclear. We present clinical and immunological data collected in a cohort of HIV-infected young individuals during the first wave of COVID-19 pandemic. SARS-CoV-2 RNA, virus-specific antibodies, as well as the expression of factors involved in the anti-viral immune response were analyzed. Moreover, we set up an in vitro coinfection assay to study the mechanisms correlated to the coinfection process. Our results did not show any increased risk of severe COVID-19 in HIV-positive young individuals. In those subjects who contracted SARS-CoV-2 infection, an increase in IL-10 expression and production was observed. Furthermore, in the in vitro coinfection assay, we revealed a reduction in SARS-CoV-2 replication associated to an upregulation of IL-10. We speculate that IL-10 could play a crucial role in the course of SARS-CoV-2 infection in HIV-positive individuals. These results might help defining clinical management of HIV/SARS-CoV-2 co-infected young individuals, or putative indications for vaccination schedules in this population.

3 May 2022 in Children
Verified
Journal Article
Open access
PDF file
Valeria RubinacciValeria Rubinacci
Valeria Rubinacci
MFMara Fumagalli
Mara Fumagalli
Giulia MeravigliaGiulia Meraviglia
Giulia Meraviglia
LGLaura Gianolio
Laura Gianolio
ASAnna Sala
Anna Sala
VGVania Giacomet
Vania Giacomet
Congenital cytomegalovirus infection (cCMV) is the most common congenital viral infection, with a consistent rate of morbidity, mortality, and long-term sequelae, especially in the case of late diagnosis. Nevertheless, a universal screening for CMV is not currently recommended, and global awareness about this infection, as well as accurate and shared indications on follow-up and treatment, are still lacking. We reviewed data about 59 suspect cCMV cases who referred to our center from 2014 to 2021. We report 41 cases of confirmed cCMV diagnosed at birth, with clinical or radiological abnormalities in 36.6% of them. Other five patients received a late diagnosis and all presented neurological impairment. Twelve patients received therapy with Valganciclovir within the first month of life, with favorable outcome in nine cases. Therapy after the first month of life was attempted in four patients, with improvement in one case. The overall awareness about cCMV infection was 32.6%. Considering our population, maternal serological screening followed by targeted testing of neonates could be an effective strategy. Some aspects of cCMV infection management should be further investigated, such as indication of treatment after the first month of life or in asymptomatic patients. Awareness about the infection should be improved to implement preventive strategies.

23 May 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
FMFrancesca Musto
Francesca Musto
MSmarta stracuzzi
marta stracuzzi
ECElisa Crivellaro
Elisa Crivellaro
Valeria RubinacciValeria Rubinacci
Valeria Rubinacci
ACAlessandro Cibarelli
Alessandro Cibarelli
VGVania Giacomet
Vania Giacomet
Hepatitis C virus (HCV) infection natural history and management in the pediatric population are still debated. We retrospectively evaluated the outcome of a HCV pediatric population managed at the Pediatric Infectious Disease Unit of Luigi Sacco Hospital (Milan, Italy) from January 1997 to January 2022 (median follow-up 10 years) and we focused on the role of new drugs and transient elastography. Fifty-seven patients were enrolled: 8 (14%) had a spontaneous clearance, 33 were treated (58%), 7 (12%) were not treated because they were under 12 years old and 9 were lost at follow-up. HCV RNA was undetectable in all treated patients at the end of therapy, after 12 weeks (SVR12) and for the rest of their follow-up. All patients treated underwent elastography before and 1 year after therapy. Median stiffness pretherapy was 5.6 kPa, and 9 patients (16%) had abnormal transient elastography (>7 kPa, median 8.7 kPa). Median stiffness after treatment in the abnormal group was 6.8 kPa. Direct-acting antiviral agents are a safe and effective therapy for HCV chronic infection in the pediatric population. Liver elastography is normal in many vertically infected children before 12 years, but, when abnormal, it shows a significant improvement after direct-acting antiviral agent treatment. Further studies are needed to evaluate the role of elastography at diagnosis and follow-up in children.

31 October 2022 in Medico e Bambino Pagine Elettroniche
Verified
Journal Article
Closed access
GGGabriella Guida
Gabriella Guida
NGNicolò Garancini
Nicolò Garancini
Valeria RubinacciValeria Rubinacci
Valeria Rubinacci
GZGianvincenzo Zuccotti
Gianvincenzo Zuccotti
VGVania Giacomet
Vania Giacomet
The paper presents the case of Pakistani girl with low-grade fever, malaise and non-specific abdominal pain, finally diagnosed with pulmonary and extra-pulmonary TB.